JAZZ
Closed
Jazz Pharmaceuticals Plc
109.44
+3.32 (+3.13%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 106.12
Day's Range: 105.26 - 111.25
Send
sign up or login to leave a comment!
When Written:
147.16
Jazz Pharmaceuticals PLC is a biopharmaceutical company that focuses on developing and commercializing medicines for patients with serious and life-threatening diseases. The company was founded in 2003 and is headquartered in Dublin, Ireland, with additional offices in the United States and Europe.
Jazz Pharmaceuticals has a portfolio of products that includes both commercialized and investigational drugs. Its commercialized products include Xyrem (sodium oxybate) for the treatment of narcolepsy, Defitelio (defibrotide sodium) for the treatment of severe hepatic veno-occlusive disease, and Erwinaze (asparaginase Erwinia chrysanthemi) for the treatment of acute lymphoblastic leukemia.
The company's investigational drugs focus on areas such as sleep disorders, oncology, and neuroscience. Its pipeline includes JZP-110 for the treatment of excessive sleepiness in patients with narcolepsy and obstructive sleep apnea, and JZP-458 for the treatment of acute lymphoblastic leukemia.
Jazz Pharmaceuticals is committed to sustainability and social responsibility, with a focus on reducing its environmental impact and supporting the communities in which it operates. The company is listed on the NASDAQ stock exchange under the ticker symbol "JAZZ."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Jazz Pharmaceuticals has a portfolio of products that includes both commercialized and investigational drugs. Its commercialized products include Xyrem (sodium oxybate) for the treatment of narcolepsy, Defitelio (defibrotide sodium) for the treatment of severe hepatic veno-occlusive disease, and Erwinaze (asparaginase Erwinia chrysanthemi) for the treatment of acute lymphoblastic leukemia.
The company's investigational drugs focus on areas such as sleep disorders, oncology, and neuroscience. Its pipeline includes JZP-110 for the treatment of excessive sleepiness in patients with narcolepsy and obstructive sleep apnea, and JZP-458 for the treatment of acute lymphoblastic leukemia.
Jazz Pharmaceuticals is committed to sustainability and social responsibility, with a focus on reducing its environmental impact and supporting the communities in which it operates. The company is listed on the NASDAQ stock exchange under the ticker symbol "JAZZ."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








